FLORONE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for FLORONE (FLORONE).
Glucocorticoid receptor agonist; induces phospholipase A2 inhibitory proteins (lipocortins), which suppress release of arachidonic acid and subsequent prostaglandin/leukotriene synthesis; also suppresses cytokine production and immune cell migration.
| Metabolism | Primarily hepatic via CYP3A4-mediated oxidation; undergoes glucuronidation and sulfation; excreted renally. |
| Excretion | Renal (approximately 80% as metabolites, <5% unchanged), biliary/fecal (remainder). |
| Half-life | Terminal elimination half-life of approximately 2-3 hours; clinical context: duration of action may extend beyond half-life due to tissue binding. |
| Protein binding | Approximately 90% bound to plasma proteins, primarily albumin and corticosteroid-binding globulin (CBG). |
| Volume of Distribution | Apparent volume of distribution approximately 0.5-1.0 L/kg; indicates distribution into total body water with some tissue binding. |
| Bioavailability | Topical: negligible systemic absorption (less than 5% through intact skin); ocular: minimal systemic absorption; oral: not available; parenteral: not applicable. |
| Onset of Action | Topical: rapid within minutes (vasoconstriction); systemic: not applicable for routine use; ocular: within 1-2 hours for anti-inflammatory effect. |
| Duration of Action | Topical vasoconstriction: 2-4 hours; anti-inflammatory effects persist for 24-48 hours after single dose; clinical note: frequency of application every 6-12 hours for dermatoses. |
Topical: Apply a thin layer to affected skin once or twice daily. Maximum use: 45 g/week.
| Dosage form | CREAM |
| Renal impairment | No dose adjustment required for topical use; systemic absorption is negligible. |
| Liver impairment | No dose adjustment required for topical use; systemic absorption is negligible. |
| Pediatric use | Children ≥2 years: Apply a thin layer once or twice daily; use the least potent formulation and limit treatment duration. Children <2 years: Not recommended due to risk of systemic toxicity. |
| Geriatric use | Use with caution: apply minimal amount for shortest duration due to increased risk of skin atrophy and systemic absorption. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for FLORONE (FLORONE).
| Breastfeeding | It is not known whether topical diflorasone diacetate is excreted in human milk. Systemically administered corticosteroids appear in human milk and could suppress growth, interfere with endogenous corticosteroid production, or cause other adverse effects. Use with caution in nursing mothers; do not apply to breast area to avoid infant ingestion. M/P ratio: Not determined. |
| Teratogenic Risk | FLORONE (diflorasone diacetate) is a topical corticosteroid. Systemic absorption is minimal with topical use, but if significant absorption occurs, corticosteroids may cause fetal harm. In animal studies, corticosteroids have been shown to be teratogenic. There are no adequate and well-controlled studies in pregnant women. First trimester: Use only if potential benefit justifies risk to fetus. Second and third trimesters: Prolonged use may lead to fetal adrenal suppression. Avoid high potency formulations over large areas. |
■ FDA Black Box Warning
None.
| Serious Effects |
["Hypersensitivity to any component of the formulation","Untreated bacterial, fungal, viral, or tuberculous skin infections","Perioral dermatitis","Acne vulgaris","Rosacea"]
| Precautions | ["Topical corticosteroids may cause HPA axis suppression, especially with prolonged use, large surface area, or occlusive dressings.","Systemic absorption may produce reversible HPA axis suppression, Cushing's syndrome, hyperglycemia, and glucosuria.","Use with caution in pediatric patients; may be more susceptible to systemic toxicity.","May cause local adverse reactions including atrophy, striae, telangiectasias, and contact dermatitis.","Use in skin infections may mask or worsen infection; appropriate antimicrobial therapy should be used if infection is present."] |
Loading safety data…
| Fetal Monitoring | Monitor maternal adrenal function with prolonged use or large surface area application. Assess fetal growth via ultrasound if prolonged high-dose use. Monitor for signs of fetal adrenal suppression (e.g., poor feeding, hypoglycemia) in neonates after maternal use. |
| Fertility Effects | No data on human fertility effects. Animal studies with corticosteroids have shown impaired fertility at high doses. Clinically significant effects are unlikely with topical use due to minimal systemic absorption. |